Comprehensive Drug Collection Summary
========================================

Pipeline Drugs Found: 218
FDA Documents: 0
Drugs.com Documents: 21
Clinical Trials: 1046
Total Documents: 1067
Success: False

Pipeline Drugs by Company:
==============================

Merck & Co.:
------------
   1. Patritumab
   2. NCT04938830
   3. NCT05624554
   4. NCT03976323
   5. Sotatercept is
   6. NCT04233879
   7. OMAHA1
   8. NCT06430801
   9. NCT06203210
  10. NCT06864169
  11. Ovarian01
  12. NCT06052059
  13. NCT04945460
  14. LSD1
  15. Esophageal01
  16. Clesrovimab is
  17. NCT03834506
  18. NCT05631093
  19. NCT06698042
  20. NCT06630286
  21. NCT05933577
  22. NCT06504394
  23. NCT05947851
  24. drug conjugate zilovertamab
  25. NCT06177912
  26. NCT06170788
  27. NCT06041802
  28. Nemtabrutinib is
  29. NCT06456346
  30. IgG1
  31. Ifinatamab
  32. Decline Accept
  33. Sacituzumab
  34. NCT06571045
  35. NCT06664801
  36. Nemtabrutinib was acquired
  37. except as
  38. NCT06136559
  39. Lung02
  40. NCT06307431
  41. NCT06637423
  42. NCT06393374
  43. NCT06459180
  44. patritumab deruxtecan
  45. NCT06780085
  46. NCT06630299
  47. NCT06172478
  48. NCT06356311
  49. Lung01
  50. NCT05052996
  51. GI01
  52. NCT06623422
  53. NCT04624204
  54. NCT04736706
  55. NCT04233216
  56. subcutaneous pembrolizumab
  57. NCT05952856
  58. NCT05612035
  59. NCT06312137
  60. Prostate01
  61. NCT04575597
  62. Ifinatamab deruxtecan
  63. NCT06132958
  64. NCT05722015
  65. NCT04223778
  66. NCT04776252
  67. PARP1
  68. NCT06079879
  69. PCSK9
  70. ov65
  71. NCT06925737
  72. NCT06956235
  73. Sotatercept is an
  74. NCT05270668
  75. NCT05696080
  76. bezlotoxumab
  77. NCT06428409
  78. drug conjugate sacituzumab
  79. drug conjugate ifinatamab
  80. NCT06305767
  81. HER3
  82. Sotatercept
  83. Ifinatamab deruxtecan is
  84. NCT06660654
  85. PanTumor02
  86. Therapeutic protein zilovertamab
  87. NCT07013487
  88. Small molecule nemtabrutinib
  89. NCT05766501
  90. Quavonlimab
  91. NCT05464420
  92. NCT04619004
  93. Quavonlimab is
  94. quavonlimab
  95. Small molecule patritumab
  96. Nemtabrutinib was
  97. Clesrovimab is a
  98. NCT06305754
  99. NCT06644781
  100. CDH6
  101. NCT04938817
  102. Sacituzumab tirumotecan
  103. Pembrolizumab
  104. NCT04944992
  105. NCT06465186
  106. NCT06596694
  107. NCT06482112
  108. NCT03765918
  109. zilovertamab vedotin
  110. Quavonlimab is being
  111. patritumab
  112. Quavonlimab is an
  113. NCT06788912
  114. NCT05406401
  115. NCT06077760
  116. NCT05633992
  117. NCT04380636
  118. NCT04728893
  119. drug conjugate quavonlimab
  120. NCT03834493
  121. NCT05587712
  122. Pembrolizumab is
  123. NCT06008756
  124. Zilovertamab vedotin was
  125. NCT05425732
  126. NCT05139017
  127. except as noted
  128. NCT05420961
  129. NCT05952869
  130. PARP2
  131. NCT03162536
  132. NCT06428396
  133. NCT05144841
  134. NCT04223791
  135. Peptide ifinatamab
  136. NCT04896008
  137. Zilovertamab
  138. Nemtabrutinib
  139. NCT05705349
  140. NCT07033494
  141. NCT06492291
  142. NCT04191096
  143. Bispecific antibody nemtabrutinib
  144. NCT06045507
  145. Zilovertamab vedotin
  146. nemtabrutinib
  147. NCT06330064
  148. NCT05877547
  149. NCT05526716
  150. Clesrovimab
  151. NCT05393037
  152. Sotatercept was
  153. NCT06824467
  154. Peptide ifinatamab deruxtecan
  155. NCT06351631
  156. NCT05630755
  157. NCT06997497
  158. pembrolizumab
  159. drug conjugate patritumab
  160. NCT06099782
  161. NCT04767373
  162. NCT06136624
  163. NCT06667700
  164. NCT06664502
  165. NCT06717347
  166. PanTumor01
  167. Sotatercept was acquired
  168. sacituzumab tirumotecan
  169. NCT07060807
  170. NCT03976362
  171. NCT05458297
  172. NCT06450366
  173. sacituzumab
  174. Pembrolizumab is a
  175. sotatercept
  176. NCT06651281
  177. TROP2
  178. Patritumab deruxtecan
  179. NCT06345729
  180. NCT06161025
  181. Patritumab deruxtecan is
  182. NCT06074588
  183. NCT03066778
  184. Sacituzumab tirumotecan is
  185. NCT04564547
  186. NCT06422143
  187. PARP3
  188. NCT06136650
  189. ROR1
  190. NCT05116189
  191. Breast04
  192. NCT06721156
  193. clesrovimab
  194. zilovertamab
  195. Nemtabrutinib is an
  196. ifinatamab deruxtecan
  197. NCT03867084
  198. ifinatamab
  199. dose combination quavonlimab
  200. NCT05569954
  201. Zilovertamab vedotin is
  202. NCT06312176

Bristol Myers Squibb:
---------------------
   1. ipilimumab
   2. nivolumab and
   3. relatlimab
   4. enasicon
   5. dasatinib
   6. repotrectinib
   7. nivolumab and relatlimab
   8. elotuzumab
   9. belatacept
  10. TYK2
  11. fedratinib
  12. luspatercept
  13. abatacept
  14. deucravacitinib
  15. nivolumab and hyaluronidase
  16. nivolumab


Summary by Company:
====================
  Merck & Co.: 202 drugs
  Bristol Myers Squibb: 16 drugs
